I'm Watching MNKD

I've been watching this a while. After all, if you know anyone who is insulin dependent, the option of getting insulin sans injection is amazing! Recent clinical trials showed it is as effective as injected insulin. MNKD is hoping for a Spring 2010 approval for Afresa.

I had hoped to buy it in the mid 6s but it doesn't seem to be getting there.

From Diabetes Drug War:
The drug still expected the next big new release with Blockbuster potential is an inhalable insulin from MannKind Corp. (NASDAQ: MNKD). Afresa is to be its name. Despite past woes of inhalable insulin, MannKind shares were hitting 52-week highs in June and its shares are still up 20% from three months ago. A late-stage study showed that Afresa’s performance was similar to injectable insulin. The company recently sold a 7.4 million shares secondary offering to raise cash for this launch, and its CEO took 1 million shares of the offering. The thought was that MannKind would secure a partner for marketing and development, but the recent stock offering gives it more internal options ahead of what is believed to be a Spring-2010 FDA approval action. Pfizer Inc (NYSE: PFE) has been thought of as a partner as it moved Exubera inhaled-insulin patients to MannKind’s experimental product. The two companies had been partners until Pfizer pulled Exubera from the market in 2007.
Company website
Google Chart
2nd quarter financial results
Afresa market potential